Policlinico di Bari
Bari, 70124, Italy
NCT Number: NCT06719999
The study aims to explore the effects of a tailored nutritional intervention for maintaining (normal-weight subjects) or reducing (overweight or obese subjects) body weight. In a subgroup of patients with prediabetes/T2DM, the effect of the nutritional intervention by Mediterranean lunch boxes developed in the PRIMA project on gluco-lipid homeostasis will be also evaluated. Secondary objectives are to evaluate the nutritional and functional benefits of the intervention strategies on pathogenetic factors affecting metabolic and pro-inflammatory status and intestinal permeability.
This study is active but is not currently recruiting participants.
18 year–100 year
All sexes
Interventional
Not applicable
Bari, 70124, Italy
Protocol summary The study aims to explore the effects of a tailored nutritional intervention for maintaining (normal-weight subjects) or reducing (overweight or obese subjects) body weight. In a subgroup of patients with prediabetes/T2DM, the effect of the nutritional intervention by Mediterranean lunch boxes developed in the PRIMA project on gluco-lipid homeostasis will be also evaluated. Secondary objectives are to evaluate the nutritional and functional benefits of the intervention strategies on pathogenetic factors affecting metabolic and pro-inflammatory status and intestinal permeability.
Patients All enrolled participants (n=450, age 25-65) will undergo, following written informed consent, a 12-weeks, controlled, randomized, multicenter clinical study with multiple arms conducted on normal weight, overweight or obese subjects with or without prediabetes or other metabolic risk factors in Italy and Lebanon.
Study design Participants will be assigned to the healthy group (HG, n= 150) or to the dysmetabolic group (DG, n=300) according to a previous clinical assessment. The two groups will be comparable for age/gender composition. In each group, subjects will be randomized to continue the ongoing diet (controls) or to receive one of the lunch boxes developed in the project (L-MedFood or F-MedFood, ~600 kcal) 3-times/week during 12 weeks (treatment). In the treated groups, healthy subjects will receive the L-MedFood lunch box, the overweight/obese subjects, with or without prediabetes/T2DM, will receive the F-MedFood Box. The consumption of lunch boxes will be associated, in all enrolled subjects, with the use of iMFood, an interactive and easy-to-understand APP developed in this project and fulfilling the goal of a new Agro-Food Value Chain solution, to enable the transition to healthy and sustainable dietary behavior.
Groups
The different arms of the study will be as follows:
Duration The study is planned to last 12 weeks.
Outputs In all arms of the study, the primary outcomes are weight loss and satisfaction index. Secondary outcomes include changes in gluco-lipid homeostasis and in visceral and liver fat quantitative ultrasonography, adherence to Mediterranean diet (assessed and monitored by the validated score MEDI-LITE). Exploratory analyses will include analyses of inflammatory status, intestinal permeability as assessed by oral quadruple test ingestion, gut microbiota profile and metabolomic analysis. Cause-and-effect relationships between B4HT and risk reduction and decrease in obesity rate and other metabolic abnormalities.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
lunch boxes developed in the PRIMA project (L-MedFood or F-MedFood, ~600 kcal)
Time frame: From enrollment to the end of treatment at 12 weeks
The primary outcome isweight loss
Time frame: From enrollment to the end of treatment at 12 weeks
Change in glycemic profile
Time frame: From enrollment to the end of treatment at 12 weeks
Change in Lipid profile
Time frame: From enrollment to the end of treatment at 12 weeks
Change in AST, ALT, and GGT
Time frame: From enrollment to the end of treatment at 12 weeks
Change in abdominal fat depostion
Time frame: From enrollment to the end of treatment at 12 weeks
Assesment of liver fat accumulation
Time frame: At baseline and at the end of treatment (12 weeks)
Assessment of serum inflammatory markers such as Interleukins and cytokines
Time frame: At baseline and at the end of treatment (12 weeks)
Assessment of fecal gut microbiota composition
University of Bari
Other
Box for Health by Tradition & Innovation (B4HT): Promoting Sustainable Mediterranean Diet by Healthy Foods
Acronym: PRIMA-B4HT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06835933
Body Weight, Deglutition Disorders
Seoul, South Korea
View Trial DetailsNCT07083557
Atherosclerotic Disease, Atrophy
Columbia, Missouri, United States
View Trial DetailsNCT06890975
Behavior, Body Weight
Sommerville, Massachusetts, United States
View Trial DetailsNCT06915090
Behavior, Body Weight
Worcester, Massachusetts, United States
View Trial Details